I-Mab announced that Dr. Zheru Zhang resigned from his position as the President of the Company and a director of the board effective from August 31, 2022 and was appointed as the President for I-Mab Hangzhou an investee of the Company with a comprehensive biologics manufacturing facility in Hangzhou, China. Mr. Jielun Zhu resigned from his position as the Chief Strategy Officer of the Company on July 31, 2022 to pursue other interests.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | +6.67% | -4.19% | -15.79% |
Jun. 06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
Jun. 05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.79% | 121M | |
+56.89% | 809B | |
+39.52% | 624B | |
-6.55% | 351B | |
+7.92% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 166B | |
-2.57% | 157B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-Mab Announces Management Changes